INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results
– Infrastructure: DBM Global fourth quarter revenue of $225.7 million –– Life Sciences: MediBeacon®Transdermal GFR (“TGFR”) system received FDA approval […]
American Shared Hospital Services Announces Fourth Quarter and Full Year 2024 Earnings Conference Call
SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider […]
Kirby Corporation Announces Date for 2025 First Quarter Earnings Release and Earnings Webcast
HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby”) (NYSE: KEX) will announce its 2025 first quarter results at […]
Gray Announces AR Securitization Facility increase to $400 million and extension to 2028 and Revolving Credit Facility increase to $700 million
ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) — Gray Media, Inc. (“Gray” or the “Company”) (NYSE: GTN) today announced that it […]
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial – – […]
Theriva™ Biologics anuncia resultados positivos de la segunda reunión del Comité independiente para la monitorización de los datos de VIRAGE, el ensayo clínico de Fase 2b de VCN-01 de la empresa en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico
ROCKVILLE, Maryland, March 31, 2025 (GLOBE NEWSWIRE) — Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada en fase clínica que […]
Newton Golf Company to Host Fourth Quarter and Full-Year 2024 Earnings Call on March 31, 2025
CAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (Nasdaq: NWTG), a developer of performance-focused […]
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the […]
VEON Announces 2025 AGM and Board Nominees
Dubai, March 31, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator, (“VEON” or the “Company”), today announced that […]
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
More than 92% of schizophrenia patients taking TEV-‘749 in the SOLARIS survey were satisfied or very satisfied with the initiation […]
